Database→Liraglutide

Tier 1Weight LossMetabolicCardiacPREMIUM

Liraglutide

Liraglutide (Victoza / Saxenda)

FDA approved: Victoza (T2D, 2010; CV risk reduction, 2017; pediatric T2D 10+, 2019), Saxenda (weight management adults, 2014; adolescents 12+, 2020). Generic liraglutide approved 2024 (T2D) and 2025 (weight loss). EMA approved. WADA: not currently prohibited but GLP-1 class under active surveillance.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Liraglutide is the first long-acting GLP-1 receptor agonist, a once-daily subcutaneous injection with 97% homology to human GLP-1. The SCALE program demonstrated 8.0% mean weight loss at 56 weeks. The LEADER trial (n=9,340) demonstrated 13% MACE reduction and significant cardiovascular death and all-cause mortality reduction in T2D. Now available as the first generic GLP-1 for weight loss (August 2025). Largely superseded by semaglutide and tirzepatide for new prescriptions, but retains relevance as the most affordable GLP-1 option with the longest safety track record.

🔒

Full Profile: Premium Members Only

The complete Liraglutide profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use